Table 1.
Characteristics of HIV-Positive Kidney-Transplant Recipients at Baseline.*
| Characteristic | Patients (N = 27) |
|---|---|
| Age — yr | |
| Median | 41 |
| Interquartile range | 39–43 |
| Male sex — no. (%) | 15 (56) |
| Race — no (%)† | |
| Black | 26 (96) |
| Mixed race | 1 (4) |
| Cause of chronic kidney disease — no. (%) | |
| Hypertension | 1 (4) |
| Membranous glomerulonephritis | 1 (4) |
| Biopsy-confirmed HIV-associated nephropathy | 5 (19) |
| Presumed HIV-associated nephropathy | 20 (74) |
| CD4 T-cell count — cells/mm3 | |
| Median | 288 |
| Interquartile range | 236–511 |
| Positive for hepatitis B surface antigen — no. (%) | 3 (11) |
| ART regimen — no. (%) | |
| Protease inhibitor–based therapy | 11 (41) |
| NNRTI-based therapy | 16 (59) |
| Antibody induction therapy‡ | |
| ATG | |
| No. of patients (%) | 10 (37) |
| Cumulative dose — mg | |
| Median | 475 |
| Interquartile range | 400–750 |
| Thymoglobuline | |
| No. of patients (%) | 17 (63) |
| Cumulative dose — mg | |
| Median | 600 |
| Interquartile range | 450–1000 |
*
ART denotes antiretroviral therapy, HIV human immunodeficiency virus, and NNRTI nonnucleoside reverse-transcriptase inhibitor.
†
Race was self-reported.
‡
Antibody induction therapy was performed with the use of rabbit antithymocyte globulin (ATG [Fresenius] or Thymoglobuline [Sanofi]).